enVVeno Medical (NVNO) Cash & Equivalents (2017 - 2026)

enVVeno Medical's Cash & Equivalents history runs 10 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 11.58% year-over-year to $2.6 million in Q1 2026; TTM through Mar 2026 was $2.6 million, a 11.58% decrease from a year earlier, with the FY2025 full-year figure at $3.1 million, up 74.74% from the prior year.
• Cash & Equivalents slipped to $2.6 million in Q1 2026 per NVNO's latest filing, from $3.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $51.3 million in Q1 2022 and bottomed at $1.5 million in Q3 2025.
• The 5-year median for Cash & Equivalents is $2.9 million (2025), against an average of $7.1 million.
• Across the five-year window, Cash & Equivalents tumbled 95.57% in 2023 and jumped 262.21% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $4.6 million in 2022, then slipped by 20.53% to $3.6 million in 2023, then plunged by 51.55% to $1.8 million in 2024, then soared by 74.74% to $3.1 million in 2025, then decreased by 15.27% to $2.6 million in 2026.
• Per Business Quant, the three latest NVNO Cash & Equivalents figures stand at $2.6 million (Q1 2026), $3.1 million (Q4 2025), and $1.5 million (Q3 2025).